Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Director departure
Appointed director
Cyclerion Therapeutics, Inc. (CYCN) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/19/2023 8-K Quarterly results
07/12/2023 8-K Other Events  Interactive Data
06/01/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement CAMBRIDGE, Mass., June 1, 2023"
05/25/2023 8-K Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial ...
Docs: "Articles of Amendment to the Restated Articles of Organization of the Company, as amended"
05/15/2023 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "Articles of Amendment to the Restated Articles of Organization of the Company",
"CAMBRIDGE, Mass., May 15, 2023"
04/03/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement CAMBRIDGE, Mass., April 3, 2023"
03/22/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Cyclerion Reports Corporate Update and Full Year 2022 Financial Results CAMBRIDGE, Mass., March 22, 2023"
11/29/2022 8-K Quarterly results
11/22/2022 8-K Quarterly results
10/06/2022 8-K Quarterly results
09/30/2022 8-K Quarterly results
08/09/2022 8-K Quarterly results
Docs: "Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results Positive topline results for CY6463 announced in two clinical studies in patients with Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes and Cognitive Impairment Associated with Schizophrenia Study in Alzheimer’s Disease with vascular pathology enrollment ongoing Appointed Steven E. Hyman, M.D. to its Board of Directors CAMBRIDGE, Mass., Aug. 9, 2022"
07/28/2022 8-K Quarterly results
07/26/2022 8-K Appointed a new director
Docs: "Renowned neuroscience leader to further long-term clinical research strategy and external collaborations"
06/15/2022 8-K Quarterly results
06/10/2022 8-K Quarterly results
06/03/2022 8-K Quarterly results
05/04/2022 8-K Quarterly results
02/24/2022 8-K Quarterly results
11/09/2021 8-K Quarterly results
Docs: "Cyclerion Therapeutics Reports Third Quarter 2021 Financial Results and Corporate Update First patients enrolled in study in Cognitive Impairment Associated with Schizophrenia Patient screening underway in study in Alzheimer’s disease with vascular pathology Enrollment ongoing in study in Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes ; Topline clinical results expected in H1 2022 CAMBRIDGE, Mass., November 9, 2021 — Cyclerion Therapeutics, Inc. , a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, reported today results for the third quarter 2021 and provided general corporate and pipeline updates. “Cyclerion has made pipeline progress with three ongoing clinical studies related to CY6463, our le..."
10/28/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
09/30/2021 8-K Investor presentation
Docs: "Corporate Presentation"
08/19/2021 8-K Quarterly results
07/29/2021 8-K Quarterly results
Docs: "Cyclerion Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update Continuing to progress clinical development of CY6463, a first-in-class, CNS-penetrant soluble guanylate cyclase stimulator for the treatment of neurological diseases associated with cognitive impairment"
06/25/2021 8-K Quarterly results
06/04/2021 8-K Quarterly results
05/04/2021 8-K Quarterly results
04/27/2021 8-K Quarterly results
04/26/2021 8-K Quarterly results
03/19/2021 8-K/A Quarterly results
03/18/2021 8-K Quarterly results
01/13/2021 8-K Quarterly results
12/21/2020 8-K Resignation/termination of a director
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : December 16, 2020 CYCLERION THERAPEUTICS, INC. Massachusetts 001-38787 83-1895370 301 Binney Street Cambridge, Massachusetts 02142 Registrant's telephone number, including area code: 327-8778 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-co..."
10/14/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy